Default Category
-
Alta and SAIT: A Potential Private-Public Partnership
Michael Roberts; Travis GuayCase IVEY-9B13M100-ELeadership and People Management, StrategyA proposed private-public partnership (P3) involves a Calgary-based private enterprise, Alta Injection Molding (Alta), the Southern Alberta Institute of Technology (SAIT) and the government of Canada. Alta has been chosen to collaborate with SAIT because it developed a unique way to generate revenue throughout its value chain. Alta’s strategy towards fostering innovation revolves around a seven-step approach to turnkey innovation. In this P3, Alt...Starting at €8.20
-
Windmill Microlending: Converting Potential to Prosperity
Catherine Pearl; Michael Roberts; Channing BrownCase IVEY-9B20M084-EEntrepreneurship, StrategyWindmill Microlending, was established in 2004 by a group of community activists who saw the need to help Canadian newcomers restart their careers. The organization offered microloans to help pay the costs of reaccreditation and training. The organization’s first chief executive officer was hired in February 2017, and by September 2017, she had formulated a new vision for the organization that would address three goals: growing the number of clie...Starting at €8.20
-
The Abraaj Group and the Acibadem Healthcare Investment (A)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214021-EFinanceThis case concerns the proposed buyout of Acibadem, a leading hospital chain in Turkey. Abraaj, a MENA region private equity firm, proposes to make its first investment in Turkey. The case highlights the role of Turkish health care reform in driving the value. The case provides an opportunity to estimate the potential return on investment as well as evaluate the structuring of the transaction.Starting at €8.20
-
The Abraaj Group and the Acibadem Healthcare Investment (B)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214022-EFinanceThis case provides an update on the ultimate outcome of the transaction presented in The Abraaj Group and the Acibadem Healthcare Investment (A).Starting at €5.74